TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03257644
Drug: Ruxolitinib phosphate cream
Normalized name: Ruxolitinib Phosphate
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib phosphate cream at the protocol-defined dose strength based on cohort assignment.
Study: NCT02590432
Drug: Linaclotide
Normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linaclotide capsules, orally, once daily.
Study: NCT02330640
Drug: ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.
Study: NCT02330640
Drug: clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.
Study: NCT02330640
Drug: asprin
Normalized name: Easprin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will be given asprin 100mg Qd within 24hours after operation,and will continue taking aspirin at the end of the study
Study: NCT01968915
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive weekly paclitaxel as intravenous infusion over 1 hour in combination with LCL161, from cycle 2 in dose escalation part or from the first cycle in dose expansion part, and will continue it until unacceptable toxicity, disease progression and/or withdrawal of consent.
Study: NCT03678506
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban 2.5 mg x 2 will be administered to patients with positive D-dimer results
Study: NCT03324373
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET.
Study: NCT03324373
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of the PI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers. Everolimus binds to an intracellular protein, FKBP-12, resulting in an inhibitory complex formation (mTORC1) and thus inhibition of mTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic elongation factor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis. In addition, everolimus inhibited the expression of hypoxia-inducible factor (e.g., HIF-1) and reduced the expression of vascular endothelial growth factor (VEGF). Inhibition of mTOR by everolimus has been shown to reduce cell proliferation, angiogenesis, and glucose uptake in in vitro and/or in vivo studies.
Study: NCT03078322
Drug: AV-101
Normalized name: AV-101
DrugBank: AV-101 (DB12878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)
Study: NCT03299322
Drug: Jia Wei Yang He granule
Normalized name: Ci Wu Jia
DrugBank: Eleuthero (DB14303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an empirical traditional Chinese medicine compound used in the treatment of asthma for a long time
Study: NCT00843687
Drug: Risperidone long-acting injectable
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00003834
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01226849
Drug: bortezomib, rituximab, ifosphamide, etoposide, carboplatin
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375mg/m2 day 1 Etoposide 100mg/m2 day 1-3 Carboplatin AUC (5) max 800 days 2 Ifosfamide continuous infusion + Mesna 5/m2/24hr day2 Bortezomib 1.3mg/m2 days 1,4,8,11 G-CSF (SC) recommended
Study: NCT02928354
Drug: Treatment A - AZD7594
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Particle size Large as a single inhaled dose of 440 µg (nominal dose), administered via DPI
Study: NCT00242710
Drug: Bazedoxifene/Conjugated Estrogen
DrugBank: Bazedoxifene (DB06401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
Study: NCT02763059
Drug: Dexamethasone 4 mg
Normalized name: dexamethasone 4 MG
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This group receives 1 hour before surgery 4 mg dexamethasone (and another 4 mg 6 hours after the first dose)
Study: NCT02561702
Drug: Mexiletine
Normalized name: Mexiletine
DrugBank: Mexiletine (DB00379)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg Mexiletine taken by mouth in capsule form 3 times daily for 5-7 days
Study: NCT00497029
Drug: fluoride varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02324049
Drug: SBC-103
Normalized name: SBC-103
DrugBank: Lesinidase alfa (DB15267)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03862586
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01361022
Drug: Lendormin tablet
Normalized name: atenolol Oral Tablet [Tenormin]
DrugBank: Brotizolam (DB09017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lendormin tablet 250mc is administrated and compared
Study: NCT01361022
Drug: Brotizolam tablet
Normalized name: brotizolam
DrugBank: Brotizolam (DB09017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brotizolam tablet 250mc is administrated and compared
Study: NCT02903914
Drug: INCB001158
Normalized name: INCB001158
DrugBank: CB-1158 (DB15286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arginase Inhibitor
Study: NCT02903914
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PD-1 Inhibitor
Study: NCT02618512
Drug: SBC-103
Normalized name: SBC-103
DrugBank: Lesinidase alfa (DB15267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBC-103 is a recombinant human alpha-N-acetylglucosaminidase (rhNAGLU). Patients were started with low dose of SBC-103 for 12 weeks and then will escalate to a higher dose.
Study: NCT00373373
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 x 400 mg/d
Study: NCT00933426
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lead-In beginning dose of 5 mg capsules by mouth once a day for 21 days in a row, followed by 7 days of rest (Days 22-28) for a 28 day cycle.
Study: NCT00933426
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50 mg/m\^2 given by vein over 1 hour on Days 1, 8, and 15 of each 28 day cycle.
Study: NCT03401372
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.3mg/m2 of bortezomib on days 1, 8, 15 and 22 of a 35-day cycle
Study: NCT03401372
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40mg of dexamethasone on days 1, 8, 15 and 22 of a 35-day cycle
Study: NCT00923520
Drug: DMS 612
Normalized name: DMS
DrugBank: Succimer (DB00566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DMS 612 on day 1 and 2 with doses starting at 3.5mg/m2 to 18.5mg/m2 every 21 days until MTD is reached
Study: NCT05414669
Drug: Allopurinol Tablet 300 mg
Normalized name: allopurinol Oral Tablet
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol 300mg was given orally for a total of 3 days, beginning a day before ESWL.
Study: NCT06159452
Drug: SAR153191-P3 drug product
Normalized name: SAR153191
DrugBank: Sarilumab (DB11767)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection
Study: NCT02021864
Drug: vitamin D3 50,000 unit
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin D3 50,000 unit/week for 8 weeks
Study: NCT03830463
Drug: CTP-692
Normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Single oral dose
Study: NCT02556346
Drug: MT-3724
Normalized name: lipase
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
Study: NCT02730923
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Therapeutic Class Aromatase inhibitor~Mode of Action Potent and highly selective non-steroidal aromatase inhibitor.~Route of Administration Oral~Dosage regimen~1 mg tablet once a day~Duration of treatment Patients may continue treatment with anastrozole until the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued per patient or investigator request.
Study: NCT00047931
Drug: VRC-HIVDNA009-00-VP
Normalized name: VP-14637
DrugBank: VP-14637 (DB12195)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01497704
Drug: YN968D1
Normalized name: YN968D1 free base
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing of YN968D1 for treatment of solid tumors
Study: NCT01070940
Drug: NG-monomethyl-L-arginine (L-NMMA)
Normalized name: NG-Monomethyl-L-arginine
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg IV priming dose + 2 mg/kg/hr IV infusion for 1 hour
Study: NCT01836029
Drug: VTX-2337
Normalized name: VTX-801
DrugBank: VTX-801 (DB17646)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLR8 Agonist
Study: NCT01836029
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01836029
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01836029
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00362440
Drug: Leptin
Normalized name: Leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00362440
Drug: Pioglitazone or metformin
Normalized name: metformin / pioglitazone
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT06159452
Drug: SAR153191-P2 drug product
Normalized name: SAR153191
DrugBank: Sarilumab (DB11767)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection
Study: NCT06159452
Drug: SAR153191-C1F3 drug product
Normalized name: SAR153191
DrugBank: Sarilumab (DB11767)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form:Solution for injection-Route of administration:Subcutaneous injection
Study: NCT01070940
Drug: NG-monomethyl-L-arginine (L-NMMA)
Normalized name: NG-Monomethyl-L-arginine
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg IV priming dose + 4 mg/kg/hr IV infusion for 1 hour
Study: NCT01070940
Drug: NG-monomethyl-L-arginine (L-NMMA)
Normalized name: NG-Monomethyl-L-arginine
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 mg/kg IV priming dose + 3 mg/kg/hr IV infusion for 1 hour
Study: NCT00529100
Drug: Pemetrexed Phase 1
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300 mg/m\^2 IV, Days 1 and 22; intermediate dose escalation level of 400 mg/m\^2 IV; then 500 mg/m\^2 IV, repeated every 21 days (q 21 days) x 2 cycles
Study: NCT00529100
Drug: Cisplatin Phase 1
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cohorts 1-3: 25 mg/m\^2 IV, Days 1-3 and 22-24 then 75 mg/m\^2 IV, q21 days x 2 cycles~Cohort 4 carried into Phase 2: 20 mg/m\^2 IV, Days 1-5 and 22-26 then 75 mg/m\^2 IV, q21 days x 2 cycles.
Study: NCT00529100
Drug: Pemetrexed Phase 2
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Concurrent phase pemetrexed IV bolus as determined by Phase 1 trial to be 500 mg/m\^2 IV on Days 1 and 22.
Study: NCT00529100
Drug: Cisplatin Phase 2
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase 2 (Cohort 4 carried over from Phase 1): 20 mg/m\^2 IV, Days 1-5 and 22-26 then 75 mg/m\^2 IV, q21 days x 2 cycles.
Study: NCT00925977
Drug: insulin Glargine + Insulin Apidra
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 12 wees treatment with Insulin Glargine + Insulin Apidra
Study: NCT00244959
Drug: anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg orally daily for 12 months
Study: NCT00903851
Drug: Lidoderm
Normalized name: Lidoderm
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients participated in an 8-week treatment period; patients at one site were to continue treatment for the entire 8 weeks while patients at two sites were to terminate treatment after 3 weeks. Commercially available Lidoderm® (lidocaine patch 5%) was provided to each patient with up to four patches applied topically 18 hours on, 6 hours off per day to the area of maximal peripheral neuropathic pain.
Study: NCT03632759
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive subcutaneous (SC) liraglutide for 8 weeks
Study: NCT03632759
Drug: Golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive subcutaneous (SC) golimumab for 8 weeks
Study: NCT01526499
Drug: Docetaxel (T)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75mg/m2 IVGTT D1;every 21days
Study: NCT03931590
Drug: [14C]-Omaveloxolone
DrugBank: Omaveloxolone (DB12513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]-Omaveloxolone 50 mg capsules
Study: NCT02573506
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
Study: NCT01828554
Drug: Xeloda
Normalized name: Xeloda
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cycle 1: Days 1-7 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Ideal Body Weight to calculate dosage. Cycle 1, Day 8-No drug.~Cycle 1: Days 9-15 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage. Days 16-21-No drug.~Cycle 2 and greater: Days 1-14 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage.
Study: NCT01651767
Drug: JNJ-47910382
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=30, 90, 300, 400 or 450, form=suspension, route=oral. Study drug will be administered once or twice daily
Study: NCT03083470
Drug: SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SOR007 will be applied topically to a target AK lesion test field twice daily for up to 28 days, or until all lesions resolve. The maximum total amount of SOR007 that will be applied daily will be 1 finger-tip unit (FTU), approximately 0.5g. No more than 25cm2, approximately 0.15% of the total body surface area, will be treated.
Study: NCT02466906
Drug: rhGM-CSF
Normalized name: rhGm-CSF
DrugBank: Regramostim (DB05386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGM-CSF was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. During adjuvant therapy of XELOX, rhGM-CSF was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15) or stopped when ANC\>20.0X109/L.
Study: NCT02753738
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet 10mg, 21 days
Study: NCT02831361
Drug: Gemigliptin
Normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02831361
Drug: Gemigliptin placebo
DrugBank: Gemigliptin (DB12412)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02831361
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study
Study: NCT03236649
Drug: Icaritin
Normalized name: Icaritin
DrugBank: Icaritin (DB12672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
Study: NCT03236649
Drug: Sorafenib Tosylate Tablets
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400mg/time, 2 tablets/time(2×200mg/tablet), 2times/day(Fasting), take orally, continuous administration until reach the standard of termination.
Study: NCT01022736
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be administered gabapentin (600 mg, orally) 1 hour prior to cardiac bypass surgery, 1 hour following extubation, then every 8 hours for a total of 4 doses.
Study: NCT01890343
Drug: florbetapir 18F
Normalized name: florbetapir (18F)
DrugBank: Florbetapir F-18 (DB09149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
Study: NCT00429091
Drug: atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will take 40 mg BID or placebo for up to four weeks.
Study: NCT01890343
Drug: 18F-FDG
Normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FTD subjects received a one-time IV bolus injection of 185 MBq of 18F-FDG.
Study: NCT02595983
Drug: Revusiran
Normalized name: Revusiran
DrugBank: Revusiran (DB16309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg Revusiran by subcutaneous (sc) injection
Study: NCT01045460
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/m\^2/day given on Days -2 and -1.
Study: NCT04664153
Drug: PF-07038124 ointment
Normalized name: LUBRICATING (PF) OPH OINT
DrugBank: PF-07038124 (DB19143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07038124 ointment at 0.01% with QD dosing for 6 weeks
Study: NCT04664153
Drug: Vehicle ointment
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle ointment with QD dosing for 6 weeks
Study: NCT02847000
Drug: Tetrahydrouridine
Normalized name: Tetrahydrouridine
DrugBank: Tetrahydrouridine (DB12484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose is by weight:~THU is supplied as 250 mg/capsule Weight 40-60kg = 2 capsules of Tetrahydrouridine. Weight 61-80kg = 3 capsules of THU. Weight 81-100kg or higher = 4 capsules of THU.~Timing between THU and Dec, Frequency of administration: Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days. Treatment on protocol monitoring continues for 52 weeks, however, subjects will have the option to continue beyond this period if it judged to be in their interests.
Study: NCT02847000
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose is by weight:~DEC is supplied as 5 mg/capsule. Weight 40-60kg = 2 capsules of Decitabine. DEC capsules are ingested \~60 minutes after THU capsules. Weight 61-80kg = 3 capsules of DEC. DEC capsules are ingested \~60 minutes after THU capsules. Weight 81-100kg or higher = 4 capsules of DEC. DEC capsules are ingested \~60 minutes after THU capsules.~Timing between THU and Dec, Frequency of administration: Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days. Treatment on protocol monitoring continues for 52 weeks, however, subjects will have the option to continue beyond this period if it judged to be in their interests.
Study: NCT00097500
Drug: exenatide
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous injection, titrated up to a maximum of 20mcg three times a day in order to meet defined blood glucose targets
Study: NCT00097500
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: subcutaneous injection, once a day, titrated as necessary in order to meet defined blood glucose targets
Study: NCT00097500
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients usual dosage
Study: NCT02789020
Drug: Rasagiline
Normalized name: Rasagiline
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rasagiline will be taken for one year at the dose of 1mg a day. and subjects will undergo functional and structural brain imaging to determine if rasagiline is slowing the progression of Parkinson's Disease in the brain.